Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.

PloS one - 1 Jan 2012

Shetty Praveenkumar K, Thamake Sanjay I, Biswas Swati, Johansson Sonny L, Vishwanatha Jamboor K

Abstract excerpt

Alternative survival pathways are commonly seen to be upregulated upon inhibition of receptor tyrosine kinases (RTK), including Her-2. It is established that treatment with Herceptin leads to selective overexpression and activation of epidermal growth factor receptor (EGFR) and Src which further contributes to oncogenesis in Herceptin resistant and triple negative breast cancer (TNBC) patients. Here, we show a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Annexin A2
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Laminin

Share to Proteoglycans

Share to Receptor, ErbB-2

Share to src-Family Kinases

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 22957061
DOI: 10.1371/journal.pone.0044299
PMCID: PMC3434131

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.PMID 22957061Read ↗

Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.Semantic proximity Read ↗

Association of annexin A2 with cancer development (Review)Semantic proximity Read ↗

Annexin A2: Its Molecular Regulation and Cellular Expression in Cancer DevelopmentSemantic proximity Read ↗

The Role of ERBB2/HER2 Tyrosine Kinase Receptor in the Regulation of Cell DeathSemantic proximity Read ↗

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast CancerSemantic proximity Read ↗

Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancersSemantic proximity Read ↗

Role of HER2/neu in tumor progression and therapy.Semantic proximity Read ↗

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.Semantic proximity Read ↗

Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cellsSemantic proximity Read ↗

A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.Semantic proximity Read ↗

AGR2, a potential prognostic and predictive biomarker and therapeutic to overcome drug resistance in HER2-overexpressing cancerSemantic proximity Read ↗

Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.